ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 113 filers reported holding ACLARIS THERAPEUTICS INC in Q1 2017. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $1,120,000 | -73.3% | 511,579 | -26.8% | 0.04% | -72.6% |
| Q1 2019 | $4,189,000 | +4.7% | 699,307 | +29.2% | 0.14% | -7.5% |
| Q4 2018 | $4,000,000 | -29.4% | 541,251 | +38.8% | 0.15% | -28.1% |
| Q3 2018 | $5,663,000 | -29.0% | 389,997 | -2.3% | 0.20% | -30.0% |
| Q2 2018 | $7,975,000 | +114.9% | 399,342 | +88.5% | 0.29% | +100.0% |
| Q1 2018 | $3,711,000 | +128.7% | 211,797 | +221.8% | 0.14% | +126.6% |
| Q4 2017 | $1,623,000 | +51.5% | 65,809 | +58.6% | 0.06% | +36.2% |
| Q3 2017 | $1,071,000 | -7.9% | 41,484 | -3.2% | 0.05% | -7.8% |
| Q2 2017 | $1,163,000 | +11.9% | 42,869 | +23.1% | 0.05% | 0.0% |
| Q1 2017 | $1,039,000 | +10.2% | 34,827 | +0.3% | 0.05% | +6.2% |
| Q4 2016 | $943,000 | – | 34,734 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |